Bioceltix (BCX) Q4 2024 earnings summary

Executive summary

• Focus on R&D in veterinary stem cell therapies, with no product sales yet and continued negative net results year-over-year.

• Major milestones in clinical trials for key products, including BCX-CM-J (dogs), BCX-CM-AD (dogs), and BCX-EM (horses).

• Significant capital raised via share issue and public grants to fund ongoing development and new manufacturing facility.

Financial highlights

• Net loss for 2024: -14.9 mln PLN, compared to -13.7 mln PLN in 2023.

• No revenue from product sales in 2024 or 2023.

• Operating expenses: 18.8 mln PLN in 2024, up from 15.8 mln PLN in 2023.

• Net cash from financing activities: 42.8 mln PLN (2024), up from 20.7 mln PLN (2023).

• Cash at year-end: 33.6 mln PLN (2024), up from 9.3 mln PLN (2023).

Outlook and guidance

• Sufficient funding secured for at least 12 months, with further grants and commercialization agreements targeted.

• Final clinical results for BCX-CM-AD expected in Q2 2025; regulatory submissions ongoing for other products.

• New manufacturing facility under construction to support future product launches.